Form 4: Spruce Biosciences CFO Samir Gharib Reports Acquisition of 154,000 Restricted Stock Units

Samir M. Gharib, CFO of Spruce Biosciences, reports the acquisition of 154,000 Restricted Stock Units (RSUs) tied to clinical development milestones.

Summary

• On March 14, 2024, Samir M. Gharib, the President and CFO of Spruce Biosciences, acquired 154,000 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of SPRB common stock each.
• The RSUs vest in four equal installments of 25% on the first, second, third, and fourth anniversaries of achieving a specified clinical development objective, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice, and the vesting is tied to clinical development objectives, which is a positive sign for the company's future.

Positives

• The vesting of RSUs is tied to the achievement of a clinical development objective, aligning executive compensation with company progress.

Risks

• The value of the RSUs is contingent on the achievement of the clinical development objective and the continued service of the reporting person.

Future Outlook

The vesting of the RSUs is contingent upon the achievement of a specified clinical development objective, suggesting a focus on advancing clinical programs.

Industry Context

This type of equity compensation is common in the biotech industry to incentivize executives and align their interests with those of shareholders, particularly in relation to achieving clinical milestones.

Comparison to Industry Standards

• Granting RSUs that vest upon achieving clinical milestones is a common practice in the biotechnology industry to align executive compensation with the company's clinical development progress.
• Comparable companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use similar equity-based compensation plans to incentivize their executives.

Stakeholder Impact

• Shareholders: The vesting of RSUs tied to clinical milestones can be seen as a positive, aligning management interests with company success.
• Employees: The achievement of clinical milestones could lead to increased company value and potential benefits for all employees.

Next Steps

• The company will need to achieve the specified clinical development objective for the RSUs to vest.
• The reporting person must maintain continuous service for the RSUs to vest.

Key Dates